GlassScriptPhysician profile
Sara E Poslaiko
NPI 1629693734
$2,120.03
in general payments reported to CMS, 2019-2025
27 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.59 · 2022: $343 · 2023: $426 · 2024: $600 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $249.99 | 2023-2025 | |
| Novo Nordisk INC | $179.56 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $179.56 | 2022-2024 | |
| Amgen INC. | $179.36 | 2022-2024 | Repatha, Otezla |
| Medtronic, INC. | $151.30 | 2025 | Venaseal |
| Astellas Pharma US INC | $146.90 | 2024 | Veozah |
| Lilly USA, LLC | $138.15 | 2022-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $127.62 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Mayne Pharma Commercial LLC | $125.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $111.09 | 2024 | Voquezna |
| Boston Scientific Corporation | $71.35 | 2024-2025 | Enroute Transcarotid Stent |
| Gilead Sciences, INC. | $65.19 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $53.04 | 2021-2022 | |
| Pfizer INC. | $49.22 | 2021-2022 | |
| Exact Sciences Corporation | $43.98 | 2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $42.13 | 2023-2024 | Thinprep 2000 Processor, Aptima |
| Sanofi-Aventis U.S. LLC | $24.90 | 2022 | |
| Lemaitre Vascular, INC. | $24.72 | 2025 | Xenosure Biologic Patch |
| Cordis US Corp. | $22.81 | 2025 | S.M.A.R.T. |
| Viiv Healthcare Company | $22.36 | 2023 | Rukobia |
| Merck Sharp & Dohme LLC | $21.09 | 2022 | |
| Fresenius Kabi USA, LLC | $19.40 | 2024 | Idacio |
| Cranial Technologies, INC | $17.93 | 2023 | Doc Band |
| Mimedx Group, INC. | $14.63 | 2025 | |
| Reprise Biomedical, INC. | $14.11 | 2025 | Miro3d |
| Dexcom, INC. | $12.43 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Poslaiko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.